[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362802-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362802-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","age-related-differences-in-severe-adverse-events-during-maintenance-therapy-with-parp-inhibitors-a-retrospective-cohort-study-in-japanese-patients-with-ovarian-cancer","Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors - A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer","","Advanced ovarian cancer has a poor prognosis despite standard surgery and chemotherapy. Maintenance therapy with PARP inhibitors, including olaparib and niraparib, can cause hematologic and non-hematologic toxicities, and safety evidence in older Japanese patients remains limited. This retrospective cohort study used Japanese administrative data to evaluate clinically significant severe adverse events, treatment interruptions, and discontinuation by age, comparing patients under 65 with those aged 65 and older using inverse probability weighting.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/age-related-differences-in-severe-adverse-events-during-maintenance-therapy-with-parp-inhibitors-a-retrospective-cohort-study-in-japanese-patients-with-ovarian-cancer/362802/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/age-related-differences-in-severe-adverse-events-during-maintenance-therapy-with-parp-inhibitors-a-retrospective-cohort-study-in-japanese-patients-with-ovarian-cancer/362802.png","ImageObject",300,407,{"name":42,"@type":43},"Fahsai","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-31","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",5,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study objective regarding PARP inhibitor maintenance therapy?","Question",{"text":63,"@type":64},"To assess how age affects the incidence of clinically significant severe adverse events, treatment interruptions, and discontinuation of PARP inhibitor maintenance in Japanese patients with ovarian cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the study designed and which patients were included?",{"text":68,"@type":64},"A retrospective cohort study used the Japanese Diagnosis Procedure Combination database, including patients who received approved PARP inhibitors after surgery and chemotherapy.",{"name":70,"@type":61,"acceptedAnswer":71},"What age-related difference was observed in severe adverse events?",{"text":72,"@type":64},"After adjustment, older patients (≥65) receiving olaparib monotherapy had a higher incidence of clinically significant neutropenia than those under 65, while other severe adverse events were not significantly different by age.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362802,1790247236,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,100,105,110,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Comic",60,"comic",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},6,"Technology",50,"technology",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},7,"Healthcare",40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},8,30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":55,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":111,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},549768702563,"https://ap-avatar.wpscdn.com/avatar/8000c4aa63b76e948b?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786536092046926083","Targeted Oncology (2026) 21:255–268  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1523-026-01202-7  \nAge‑Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors: A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer  \nKeiko Nishimyo1 · Koichi Benjamin Ishikawa1 · Daisuke Aoki1,2 · Kiyohide Fushimi3 · Tsutomu Yamazaki1  \nReceived: 21 October 2025 / Accepted: 30 January 2026 / Published online: 21 February 2026 © The Author(s) 2026  \nAbstract  \nBackground Advanced ovarian cancer carries a poor prognosis despite standard surgery and chemotherapy. Although poly (ADPribose) polymerase (PARP) inhibitors, such as olaparib and niraparib, have recently become standard maintenance therapy, they can cause hematologic and non-hematologic toxicities, and data on their safety in older Japanese patients are limited.  \nObjective We aimed to evaluate the incidence of clinically significant severe adverse events (SAEs), treatment interruptions, and discontinuation of PARP inhibitor maintenance therapy according to age in Japanese patients with ovarian cancer. Methods This retrospective cohort study used data from the Japanese Diagnosis Procedure Combination database. Patients diagnosed with ovarian cancer who received treatment with PARP inhibitors approved in Japan (olaparib, olaparib plus bevacizumab, or niraparib) after surgery and chemotherapy were included. Clinically significant SAEs were identified using diagnostic and billing codes rather than laboratory-confirmed Common Terminology Criteria for Adverse Events (CTCAE) grading. Outcomes were assessed across two age groups (\u003C 65 vs. ≥ 65 years) using inverse probability weighting to account for baseline differences.  \nResults After adjustment, the baseline characteristics were balanced among the 1083 patients included in this study (olaparib, 315; olaparib plus bevacizumab, 343; niraparib, 425) . In the olaparib group, patients aged ≥ 65 years showed a higher incidence of clinically significant neutropenia compared with those aged \u003C 65 years (incidence rate ratio 7.47; 95% confidence interval 2.37–23.5) . In contrast, no significant age-related differences were observed in the incidence of other clinically significant SAEs. Rates of hospitalization, treatment interruption, and treatment discontinuation were generally comparable between the age groups across all regimens.  \nConclusion Overall, PARP inhibitor maintenance therapy appeared to be generally tolerated in older patients in this real-world cohort. However, older individuals who received olaparib monotherapy experienced a significantly higher incidence of clinically significant neutropenia, indicating the need for careful monitoring and individualized dose management in this subgroup.  \n1 Introduction  \nOvarian cancer is the eighth most common malignancy and cause of cancer-related death among women worldwide [1] . In Japan, approximately 12,700 new cases and 5200 deaths occurred in 2024 [2] . Advanced epithelial ovarian cancer, defined as stage III–IV by the International Federation of Gynecology and Obstetrics (FIGO), carries a poor prognosis, with 5-year survival rates of 54.3% and 36.8% for stage III and IV disease, respectively [3] .  \nAccording to the current Japanese clinical guidelines, advanced epithelial ovarian cancer is primarily treated with  \nExtended author information available on the last page of the article  \ncytoreductive surgery followed by platinum-based chemotherapy, most commonly a combination of paclitaxel and carboplatin (known as TC) [4] . Since the approval of bevacizumab for use with the TC regimen in 2013, this combination has become an established and widely adopted therapeutic option in Japan. Meanwhile, poly (ADP-ribose) polymerase (PARP) inhibitors, olaparib and niraparib, were recently approved for first-line maintenance therapy in Japan, based on the SOLO1, PAOLA-1, and PRIMA trials [5–7] . Specifically, olaparib was approved for pa","cbCaih47jTh7rPTG","https://ap.wps.com/l/cbCaih47jTh7rPTG","pdf",1303327,14,"English","# Abstract\n## Background and Objective\n## Methods\n## Results\n## Conclusion\n# Introduction\n## Epidemiology and standard treatment in Japan\n## PARP inhibitors and guideline context\n## Prior trial safety findings and rationale","[{\"question\":\"What was the study objective regarding PARP inhibitor maintenance therapy?\",\"answer\":\"To assess how age affects the incidence of clinically significant severe adverse events, treatment interruptions, and discontinuation of PARP inhibitor maintenance in Japanese patients with ovarian cancer.\"},{\"question\":\"How was the study designed and which patients were included?\",\"answer\":\"A retrospective cohort study used the Japanese Diagnosis Procedure Combination database, including patients who received approved PARP inhibitors after surgery and chemotherapy.\"},{\"question\":\"What age-related difference was observed in severe adverse events?\",\"answer\":\"After adjustment, older patients (≥65) receiving olaparib monotherapy had a higher incidence of clinically significant neutropenia than those under 65, while other severe adverse events were not significantly different by age.\"}]","Age-Related Differences in Severe Adverse Events During Maintenance Therapy with PARP Inhibitors - A Retrospective Cohort Study in Japanese Patients with Ovarian Cancer | PDF",1790149121,35,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fba266140b0dc174e9ccf185e399631c.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6e89fb20f677e1f0f8c38d7ff6650399.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/18ac135708a7601dcd40cacc81eae366.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1135ba65bd67dd5e2f93340277f521b6.webp",980,1301]